 |
|
Control of Bleeding in Patients With Immune and Nonimmune Thrombocytopenia With Aminocaproic Acid
John R. Bartholomew, MD;
Ravi Salgia, PhD, MD;
William R. Bell, MD
Arch Intern Med. 1989;149(9):1959-1961.
Abstract
• Patients with thrombocytopenia have an increased risk of bleeding. We have used 18 courses of aminocaproic acid in 17 patients with either immune or nonimmune thrombocytopenia to successfully control hemorrhage associated with reduced platelet counts. The types of hemorrhage controlled included the following: vaginal, gastrointestinal, intracerebral, cutaneous, mucous membrane, subconjunctival, and renal, as well as that associated with dental extractions, tracheostomy, and sites of Penrose drains. The number of platelet and red blood cell transfusions administered decreased substantially following institution of aminocaproic acid therapy. We conclude that therapy with aminocaproic acid is safe and useful in the management of bleeding in patients with both immune and nonimmune thrombocytopenia.
(Arch Intern Med. 1989;149:1959-1961)
Author Affiliations
From the Hematology Division, Department of Medicine, The Johns Hopkins University School of Medicine and Hospital, Baltimore, Md.
Footnotes
Accepted for publication March 23, 1989.
Reprint requests to Hematology Division, Department of Medicine, The Johns Hopkins University Hospital, 600 N Wolfe St, Baltimore, MD 21205-2101 (Dr Bell).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Autologous Stem-Cell Transplantation Can Be Performed Safely Without the Use of Blood-Product Support
Ballen et al.
JCO 2004;22:4087-4094.
ABSTRACT
| FULL TEXT
Management of Immune Thrombocytopenic Purpura in Adults
Stasi and Provan
Mayo Clin Proc. 2004;79:504-522.
ABSTRACT
Bloodless Medicine and Surgery
Savarese et al.
J Intensive Care Med 1999;14:20-33.
Hemostatic Drugs
Mannucci
NEJM 1998;339:245-253.
FULL TEXT
|
